Related Experiment Video
Updated: Jun 22, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
[Insulin treatment in children]
Niels H Birkebaek1, Birgitte Hertz, Birthe S Olsen
1Børneafdelingen, Arhus Universitetshospital, Skejby, DK-8200 Arhus N. nielbirk@rm.dk
Ugeskrift for Laeger
|June 9, 2009
Summary
Intensified insulin therapy and insulin analogues in children with diabetes aim to improve metabolic regulation and reduce complications. However, clear evidence of improved glycemic control is lacking, necessitating further research.
Area of Science:
- Pediatric Endocrinology
- Metabolic Regulation
- Diabetes Management
Context:
- Microvascular complications in diabetes are linked to metabolic dysregulation.
- Intensified insulin regimens, including multiple-dose insulin (MDI) and continuous subcutaneous insulin injection (CSII), are common in pediatric diabetes care.
- The use of insulin analogues is increasing in children.
Purpose:
- To summarize the pharmacokinetics of human and analogue insulins in children.
- To evaluate the effectiveness of intensified insulin treatment regimens in pediatric diabetes.
- To identify the need for further research on analogue insulin pharmacokinetics and long-term treatment outcomes.
Summary:
- Pharmacokinetic profiles of human and analogue insulins are presented.
- Current intensified insulin treatment strategies (MDI, CSII) in children lack definitive evidence of superior glycemic control.
- Pharmacokinetic studies specifically on analogue insulin in pediatric populations are required.
Impact:
- Highlights the need for robust pharmacokinetic data on insulin analogues in children.
- Underscores the necessity of long-term randomized controlled trials to validate intensified treatment efficacy.
- Informs clinical practice and future research directions in pediatric diabetes management.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...